Astellas Pharma Inc (Astellas) is a research-oriented global pharmaceutical company that focuses on the discovery, development, production, and marketing of drugs in the fields of gene therapy, urology, nephrology, immunology, oncology and others. Its major marketed products include Xtandi, Xospata, Padcev, Betanis/Myrbetriq/Betmiga, Evrenzo, Vesicare, Harnal, Eligard, Prograf, and Funguard/ Mycamine.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Astellas conducts R&D in various areas such as urology, oncology, immunology, nephrology, and neuroscience. The company initiates its R&D with exploratory research to identify disease mechanisms and potential compounds, which are converted into drugs in optimization research. Its major global development projects include MDV3100 (enzalutamide) in Phase III clinical trials for the treatment of prostate cancer in China; ASP1517 (FG-4592) roxadustat for the treatment of anemia associated with chronic kidney disease; ASP2215 (gilteritinib) for the treatment of acute myeloid leukemia; YM178 mirabegron for neurogenic detrusor overactivity in pediatric patients; IMAB362 (zolbetuximab) for the treatment of gastric and gastroesophageal junction adenocarcinoma; and ESN364 (fezolinetant) for the treatment of vasomotor symptoms associated with menopause; ASP015K for the treatment of rheumatoid arthritis. In FY2023, the company’s R&D expenses amounted to JPY276,128 million, which as a percentage of revenue, stood at 18.2% and grew 12.2% YoY.